Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia

New England Journal of Medicine

Volumn 336, Issue 25, 1997, Pages 1781-1787

  Pui, Ching Hon ^a,b,c   Boyett, James M ^a,b   Hughes, Walter T ^a,b   Rivera, Gaston K ^a,b   Hancock, Michael L ^a   Sandlund, John T ^a,b   Synold, Timothy ^a   Relling, Mary V ^a   Ribeiro, Raul C ^a,b   Crist, William M ^a,b   Evans, William E ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b Department of Pharmacy and Medicine   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CHILD; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DNA CONTENT; DOSE TIME EFFECT RELATION; FEVER; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; NEUTROPENIA; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROBABILITY; REMISSION; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL;

EID: 0030901774     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199706193362503     Document Type: Article

References (57)

1. Fui C-H. Childhood leukemia, N Engl J Med 1995;M2;1618-30.
2. Liesehke GJ, Burgess AW, Granuloeyte colony-stimulating factor and graniilocyre-microphage colony-stimulating factor, N Engl J Mod 1992; 327:99-106.
3. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocytc colonystimulating factor of fever and ncutropcnia induced by chemotherapy In patients with small-cell lung cancer. N Engl J Mod 1991;325:164-70.
4. Ohno R, Ibmonagn M, Kobiynnhl T, et al. Effect of grnnulocyto colonystimulating factor after Intensive induction therapy in relapsed or refractory acute leukemia. N HngI J Med 1990;323:871-7.
5. Pcttengell R. Gurney H, Radford TA, et al. Granuloeyte ctilony.stimulating factor to prevent dose-limiting neutropenia in non-Hudgkin's lymphoma: a randomized controlled trial. Blood 1992;80:1430-6
6. . 6. Kantarjian HM, Estey H, O'Brlen S, et al. Granulocytc cobny-itlmubting factor supportive treatment following intensive chemotherapy in acute lymphocytlc leukemia in first remission, Cancer 1993;72:2950-5.
7. Schci'rer R, Gelssler K, Kyrie PA, et al. unmiloeyte colony-stinnil.uing iactur (G-CSF) as an adjunct to induction chemotherapy of adult acute lymphobhistic leukemia (ALL). Ann Hcmatol 1993;66:283-9.
8. Ohno R, Tomoiuga M, Ohshima T, et al. A randumized a unrolled study of granulocyte colony stimulating factor after intensive induction and consolidation therapy in patients with Acute lymphohlastic leukemia: Japan Adult Leukemia Study Group. Int J Hematol 1993;58:73-81.
9. Ohno R, Nnoc T, KnnBmarw A, et al. A double-blind controlled study of granulocyte colony-silnnilntlng factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood 1994;83:2086-92.
10. h 10. Estey E, Thall P, Andreeff M, et al. Use of granulocytc colony-stimulating ractor before, during, and after fludjnibinc plus cyrarabinc induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabinc plus cytarabine without granulocytc colony-stimulating factor. J Clin Oncol 1994;12:671-8.
11. Larson RA, Linker CA, Dodge RK, et al. Granulocytc-colony stimulating factor (filgrastim; G-CSF) reduces the time to ncutrophil recovery in adults with acute lymphoblastie leukemia receiving intensive remission induction chemotherapy: Cancer and Leukemia Group B Study 9111. Proc Am Soc Clin Oncol 1994;13:305. abstract.
12. Mayordomo JI, Rivera F, Diaz-Puente MT, et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colonystimulating factors. J Natl Cancer Inst 1995;87:803-8.
13. Dombrct H, Chastang C, Penaux P, et al. A controlled study of recombinant human granulocytc colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 1995;332: 1678-83.
14. Ottmann OG, Hoclzcr D, Graden E, et al. Concomitant granulucyte colony-stimulating factor and induction ehemoradiotherapy in adult acute lymphoblastic leukemia; a randomized phase III trial, Blood 1995;86:444-50.
15. Gissclbrecht C, Prentice HG, Baeigalupo A, et al. Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation. Lancet 1994;343:696-700. [Erratum, Lancet 1994;343:804.]
16. Stahel RA, Jost LM, Cerny T, et al. Randomized study of recombinant human granulocytc colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. J Clin Oncol 1994;12:1931-8.
17. Schriber JR, Chao NJ, Long GD, et al. Granulocyte colony-stimulating factor after allogcncic bone marrow transplantation. Blood 1994;84: 1680-4.
18. Klumpp TR, Mangan KF, Goldberg SL, Pcarlman ES, Macdonald JS. Granulocyte colony-stimulating factor accelerates neutrophil cngraftment following peripheral-blood stem-cell transplantation: a prospective, randomizcd trial. J Clin Oncol 1995;13:1323-7.
19. Dibcncdctto SP, Ragusa R, Ippolito AM, et al. Assessment of the value of treatment with granulocytc colony-stimulating factor in children with acute lymphoblastic leukemia: a randomized clinical trial. Eur J Haematol 1995;55:93-6.
20. Madero L, Muftoz A, Dfaz de Heredia A, et al. G-CSF after autologous bone marrow transplantation for malignant diseases in children. Bone Marrow Transplant 1995;15:349-51.
21. Kubota M, Akiyama Y, Mikawa H, Tsutsui T. Comparative effect of 100 versus 250 /xg/m2/day of G-CSF in pediatrie patients with neutropenia induced by chemotherapy. Pediatr Hematol Oncol 1995;12:393-7.
22. Riikoncn P, Rahiala J, Salonvaara M, Perkkiö M. Prophylactic administration of granulocyte colony-stimulating factor (filgrastim) after conventional chemotherapy in children with cancer. Stem Cells 1995;13:289-94.
23. Weite K, Reiter A, Mcmpel K, et al. A randomized phase-III study of the efficacy of granuloiryte colony-stimulating factor in children with highrisk acute lymphoblastic leukemia. Blood 1996;87:3143-50.
24. Locatclli F, Pession A, Zecca M, et al. Use of recombinant human granulocyte colony-stimulating factor in children given allogeneic bone marrow transplantation for acute or chronic leukemia. Bone Marrow Transplant 1996;17:31-7.
25. Saarinen UM, Hovi L, Juvonen E, Riikoncn P, M̈otẗoncn M, M okiper naa A. Granulocyte-colony-stimulating factor after allogeneic and autologous bone marrow transplantation in children, Med Pediarr Oncol 1996; 26:380-6.
26. Update of recommendations tor the use of hcmatupoietic colony-stimulating factors: evidence-based clinical practice guidelines, J Clin Oncol 1996;14:1957-60.
27. Furman WL, tairclough DL, Huhn RD, et al. Therapeutic effects and pharmacokinetics of recombinant human granulocytc-macrophagc colonystimulating factor in childhood cancer patients receiving myelosuppressive chemotherapy. J Clin Oncol 1991;9:1022-8.
28. Santana VM, Bowman L, Furman W, Vincent M, Souza L, Crist W. Trial of chemotherapy plus recumbinant human granulocyte colony stimulating factor in children with advanced neuroblastoma. Med Pediatr Oncol 1990;18:395. abstract,
29. Synold TW, Relling MV, Boyett JM, et al. Blast cell mcthotrexate-polyglutamatc accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest 1994;94:1996-2001.
30. Pui C-H, Rivera GK, Evans WE, et al. Current treatment and results of St. Jude studies for childhood acute lymphoblastic leukemia. Haematol Blood Transfus 1994;36:307-13.
31. Hughes WT, Pizzo PA, Wade JC, Armstrong D, Webb CD, Young LS. Evaluation of new anti-infcctive drugs for the treatment of febrile episodes in neutropenic patients. Clin Infect Dis 1992;15:Suppl 1:S206-S215.
32. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in ncutropcnic patients with unexplained tever. J Infect Dis 1990;161:381-96. [Erratum, J Infect Dis 1990;161:1316.]
33. Hughes WT, Kuhn S, Cruuidhary S, et al. Successful ehemoprophylaxis for Pnemnocystis carinii pneumonitis. N Engl J Med 1977;297:1419-26.
34. Hughes WT, Rivera GK, Schell MJ, Thornton D, Lutt L. Successful intermittent ehemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1987;316:1627-32.
35. Shcnep JL, Hughes WT, Roberson PK, et al. Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer, N Engl J Med 1988;319:1053-8.
36. Stute N, Santana VM, Rodman JH, Schell MJ, Ihle JN, Evans WE. Plwmaeokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. Blood 1992;79:2849-54.
37. D'Argenio DZ, Schumitzky A. ADAPT II: mathematical software for pharmacokinetie/pharmacodynamic systems analysis: user's guide. Los Angeles: Biomedical Simulations Resource, University of Southern California, 1992.
38. Cleverlcy WO. The 1996-97 almanac of hospital financial & operating indicators. Columbus, Ohio: Center for Healthcare Industry Performance Studies, 1996.
39. Jennrich RI, Schluchter MD. Unbalanced repeated-measures models with structured covariance matrices. Biometrics 1986;42:805-20.
40. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141-54.
41. Hughes WT, Flynn PM, Williams BG. Nosocomial infections in patients with ncopbstic diseases. In: Mayhall CG, ed. Hospital epidemiology and infection control. Baltimore: Williams & Wilkins, 1996:618-31.
42. Watari K, Asano S, Shirafuji N, et al. Serum granulocyte colony-stimulating factor levels in healthy volunteers and patients with various disorders as estimated by enzyme immunoassay. Blood 1989;73:117-22.
43. Beksac M, Uzcan M, Koc. H, Akan H, Ilhan O, Sardas OS. Circulating endogenous granulocyte colony-stimulating factor levels after bone marrow transplantation. Blood 1992;80:2946-7.
44. Miksits K, Beyer J, Sicgert W. Serum concentrations of G-CSF during high-dose chemotherapy with autologous stem cell rescue. Bone Marrow Transplant 1993;11:375-7.
45. Reisbach G, Kamp T, Welzl G, et al. Regulated plasma levels of colonystimulating factors, interleukin-6 and intcrleukin-10 in patients with acute leukaemia and non-Hodgkin's lymphoma undergoing cytoreductive chemotherapy. Br J Hacmatol 1996;92:907-12.
46. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating tac tors: evidence-based, clinical practice guidelines. J Clin Oncol 1994;2:2471-508.
47. Mirro J Jr, Hurwitz CA, Behm KG, et al. Effects of recumbinant human hematopoietic growth factors on leukemic blasts from children with acute mycloblastic or lymphoblastic leukemia. Leukemia 1993;7:1026-33.
48. Kita K, Nishii K, Ohishi K, et al. Frequent gene expression of granuJocyre colony-stimulating factor (G-CSF) receptor in CD7+ surface CDS- acute lymphoblastic leukemia. Leukemia 1993;7:1184-90.
49. Bonilla MA, Dale D, Zeidler C, et al. Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias. Br J Hacmatol 1994;88:723-30.
50. Imashuku S, Hibi S, Kataoka-Morimoto Y, et al. Myelodysplasia and acute myeloid leukaemia in cases of aplastic anaemia and congenital neutropenia following G-CSF administration. Br J Haematol 1995;89:188-90.
51. Dong F, Brynes RK, Tidow N, Weite K, Lowenbcrg B, Touw IP. Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med 1995;333:487-93.
52. Pui C-H, Relling MV, Behm FG, et al. L-asparaginase may potentiate the lenkemogcnic effect of the epipodophyllotoxins. Leukemia 1995;9: 1680-4.
53. Pui C-H, Relling MV, Rivera GK, et al. Epipodophyllotoxin-related acute myeloid leukemia; a study of 35 cases. Leukemia 1995;9:1990-6.
54. Morstyn G, Campbell L, Souza LM, et al. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1988;l:667-72.
55. Lindemann A, Herrmann F, Oster W, et al. Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy. Blood 1989;74:2644-51.
56. Dreger P, Haferlach T, Eckstein V, et al. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation; safety, kinetics of mobilization, and composition of the graft. Br J Haematol 1994;87:609-13.
57. Vey N, Molnar S, Faucher C, et al. Delayed administration of granulocyte colony-stimulating factor after autologous bone marrow transplantation: effect on granulocyte recovery. Bone Marrow Transplant 1994;14: 779-82.